Key result
In patients with cancer-associated venous thromboembolism, rivaroxaban showed no significant difference in 6-month VTE recurrence compared to enoxaparin.
Why the study?
Data on direct oral anticoagulants for treating cancer-associated thrombosis are promising but remain limited and inconsistent across the literature.
Does rivaroxaban prevent VTE recurrence compared to enoxaparin in cancer patients with symptomatic DVT or PE?
Cohort (n=150)
No
Does rivaroxaban prevent VTE recurrence compared to enoxaparin in cancer patients with symptomatic DVT or PE?
Rivaroxaban demonstrates comparable efficacy and safety to enoxaparin for the treatment of cancer-associated venous thromboembolism in a retrospective cohort.
Answers are grounded in this paper and cite their sources.
Comparable recurrence and bleeding rates support rivaroxaban as a potential CAT option; leaves open definitive equivalence pending prospective randomized trials.
Background Venous Thromboembolism (VTE) in cancer patients is associated with increased mortality and morbidity. While newer data on use of direct oral anticoagulants (DOACs) in treating cancer associated thrombosis (CAT) is promising; its data is still few and inconsistent across literature. We designed the study to assess if rivaroxaban would be an appealing alternate choice to treat CAT. Methods We conducted a retrospective study to evaluate the efficacy and safety profile of rivaroxaban versus enoxaparin in cancer patients after developing a symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE). Baseline patient characteristics and laboratory values were assessed in each arm. Primary efficacy outcome was measured by radiographically confirmed VTE recurrence at different intervals. Primary safety outcome was measured by presence of major and minor bleeding using the ISTH scale. Results Our study recruited 150 cancer patients with radiologically confirmed DVT and PE; 80 patients were evaluated in enoxaparin arm and 70 patients in rivaroxaban arm. Our results showed that there was no statistically significant difference between the incidence of VTE recurrence at 6 months between the enoxaparin and rivaroxaban arm (10% vs 14.2%, p = 0.42). Historically significant risk factors for VTE in cancer patients such as high platelet count, high leukocyte count, low hemoglobin level, high risk gastrointestinal, genitourinary and lung cancers were not found to be significantly associated with the risk of VTE recurrence. Primary safety outcome analysis also showed no statistically significant difference in major (11.2% vs 11.4%) and minor (15% vs 10%) bleeding between enoxaparin versus rivaroxaban arm respectively ( p = 0.65). Conclusion We conclude that there was no significant difference seen between the efficacy and safety profile of enoxaparin and rivaroxaban in our cancer patient population.
No takes yet. Share an insight, caveat, or question.
Faqah et al. (2020) conducted a cohort in Cancer-associated venous thromboembolism (n=150). Rivaroxaban vs. Enoxaparin was evaluated on Radiographically confirmed VTE recurrence at 6 months (p=0.42). In patients with cancer-associated venous thromboembolism, rivaroxaban showed no significant difference in 6-month VTE recurrence compared to enoxaparin.
Synapse has enriched 10 related papers. Consider them for comparative context: